ArticleCancer science2022
ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma.
Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Target FADS1-arachidonic acid-ferroptosis axis: A metabolic bridge linking matrix stiffness to PDAC stemness.Materials today. Bio · 2026Article
- Ferroptosis Resistance: Redundant Antioxidant Networks Are a Barrier to Cancer Therapy.Antioxidants (Basel, Switzerland) · 2026Review
- Co-overexpression of ELOVL2 and ELOVL5 promotes clear cell renal cell carcinoma progression through LIMK1-mediated cytoskeletal reorganization.Scientific reports · 2026Article
- Disrupting Cancer Pathways with Nanogel-Encapsulated Wheatgrass Phytopharmaceuticals for Skin Cancer Therapy.Anti-cancer agents in medicinal chemistry · 2026Review
- Alpha-linolenic acid in cancer: a predictive fate-switch framework for tumor lipid reprogramming.Frontiers in oncology · 2026Article
- Exploring the significance of fatty acid metabolism reprogramming in the pathogenesis of cancer and anticancer therapy.Annals of medicine · 2025Review
- Article
- Article
- Label-free quantitative proteomics reveals the mechanisms of Aurora kinase B in renal cell carcinoma.SAGE open medicine · 2024Article
- The Effect of Silencing Fatty Acid Elongase 4 and 6 Genes on the Proliferation and Migration of Colorectal Cancer Cells.International journal of molecular sciences · 2023Article
- A comprehensive review of the family of very-long-chain fatty acid elongases: structure, function, and implications in physiology and pathology.European journal of medical research · 2023Review
- Multi-Omics Reveals the Effect of Crossbreeding on Some Precursors of Flavor and Nutritional Quality of Pork.Foods (Basel, Switzerland) · 2023Article
- Integrating Single-Cell RNA-Seq and Bulk RNA-Seq Data to Explore the Key Role of Fatty Acid Metabolism in Breast Cancer.International journal of molecular sciences · 2023Article
- Emergence of Lipid Droplets in the Mechanisms of Carcinogenesis and Therapeutic Responses.Cancers · 2023Review
- Beyond Fluidity: The Role of Lipid Unsaturation in Membrane Function.Cold Spring Harbor perspectives in biology · 2023Review
- Review
- The emerging role of long non-coding RNAs in renal cell carcinoma progression and clinical therapyFrontiers in pharmacology · 2023Review
- Emerging roles of polyunsaturated fatty acid synthesis pathway in colorectal cancer.Animal cells and systems · 2023Review
- ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma.Cancer science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Renal cell carcinoma (RCC) features altered lipid metabolism and accumulated polyunsaturated fatty acids (PUFAs). Elongation of very long-chain fatty acid (ELOVL) family enzymes catalyze fatty acid elongation, and ELOVL5 is indispensable for PUFAs elongation, but its role in RCC progression remains unclear. Here, we show that higher levels of ELOVL5 correlate with poor RCC clinical prognosis. Liquid chromatography/electrospray ionization-tandem mass spectrometry analysis showed decreases in ELOVL5 end products (arachidonic acid and eicosapentaenoic acid) under CRISPR/Cas9-mediated knockout of ELOVL5 while supplementation with these fatty acids partially reversed the cellular proliferation and invasion effects of ELOVL5 knockout. Regarding cellular proliferation and invasion, CRISPR/Cas9-mediated knockout of ELOVL5 suppressed the formation of lipid droplets and induced apoptosis via endoplasmic reticulum stress while suppressing renal cancer cell proliferation and in vivo tumor growth. Furthermore, CRISPR/Cas9-mediated knockout of ELOVL5 inhibited AKT Ser473 phosphorylation and suppressed renal cancer cell invasion through chemokine (C-C motif) ligand-2 downregulation by AKT-mTOR-STAT3 signaling. Collectively, these results suggest that ELOVL5-mediated fatty acid elongation promotes not only cellular proliferation but also invasion in RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.